This application is for the Competing Renewal of an Institutional NRSA for combined MD and PhD training in the Medical Scientist Training Program (MSTP) at Harvard Medical School (HMS) and the Massachusetts Institute of Technology (MIT). The purpose of this training program is to meet an overwhelming need for physician scientists who will lead the translation of new research discoveries into improvements in human health. The program offers an integrated course of study combining medical education at HMS with graduate study at Harvard or MIT. For medical education, HMS offers a choice of two different programs leading to the MD degree: a problem-solving, case-based approach to learning that incorporates patient exposure and case scenarios from the onset of medical school (New Pathway), or a curriculum that emphasizes quantitative analysis and technology taught jointly with MIT (Health Sciences and Technology). For graduate study, the scope of scientific training in the program ranges from the basic sciences to translational research and bioengineering to the social sciences. The medical and scientific training components are integrated throughout the program, beginning with a course in the Molecular Biology of Human Disease and a laboratory research rotation that are taken by all MSTP students during the summer before the first academic year. The resources available to meet this mission are outstanding, including facilities and faculty from 10 pre-clinical departments at HMS, HMS-appointed faculty in both preclinical and clinical departments at seven different Harvard-affiliated teaching hospitals and institutes, and the many academic departments in the basic and social sciences at the main campuses of Harvard University and MIT in Cambridge. Students are provided guidance from before matriculation through to the end of their training by advisors with specific expertise in their area of research interest. Multiple MD-PhD-specific curricular activities foster strong relationships among each cohort and across multiple cohorts of students. 169 faculty members participate directly in the program through service on program committees and/or participation as MD-PhD student thesis advisors. The trainees are exceptionally qualified and diverse. Although not all MD-PhD students are awarded funding at the time of matriculation, the program is designed to include all students at Harvard Medical School who choose to simultaneously pursue the MD and PhD degrees, offering all program activities and mentoring support to 155 current MD-PhD students whether MSTP-funded or not. MSTP funds leverage considerable support from other training grants, individual NIH investigator awards, individual student fellowships, departmental funds, hospital funds and unrestricted institutional funds.

Public Health Relevance

The purpose of this training program is to meet an overwhelming need for physician scientists who will lead the translation of new research discoveries into improvements in human health. The program offers students the largest collection of academic laboratories in the world for research training, complemented by teaching hospitals in position to rapidly translate basic discoveries into new clinical applications. Upon completion of the training program, graduates will be poised to become future leaders in biomedical discovery, in the development of next generation diagnostic tools and therapeutics, and in shaping strategies for maximizing the clinical impact of these new discoveries.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM007753-37
Application #
8882429
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Preusch, Peter
Project Start
1979-07-01
Project End
2016-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
37
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Harvard Medical School
Department
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
Fink, Emma C; McConkey, Marie; Adams, Dylan N et al. (2018) CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132:1535-1544
Lo, Justin H; Hao, Liangliang; Muzumdar, Mandar D et al. (2018) iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 17:2377-2388
Grossman, Sharon R; Engreitz, Jesse; Ray, John P et al. (2018) Positional specificity of different transcription factor classes within enhancers. Proc Natl Acad Sci U S A 115:E7222-E7230
Olson, Calla M; Jiang, Baishan; Erb, Michael A et al. (2018) Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol 14:163-170
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Starkweather, Clara Kwon; Gershman, Samuel J; Uchida, Naoshige (2018) The Medial Prefrontal Cortex Shapes Dopamine Reward Prediction Errors under State Uncertainty. Neuron 98:616-629.e6
Reshef, Yakir A; Finucane, Hilary K; Kelley, David R et al. (2018) Detecting genome-wide directional effects of transcription factor binding on polygenic disease risk. Nat Genet 50:1483-1493
Hrvatin, Sinisa; Hochbaum, Daniel R; Nagy, M Aurel et al. (2018) Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex. Nat Neurosci 21:120-129
Stolte, Björn; Iniguez, Amanda Balboni; Dharia, Neekesh V et al. (2018) Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med 215:2137-2155
Moynihan, Kelly D; Holden, Rebecca L; Mehta, Naveen K et al. (2018) Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability. Cancer Immunol Res 6:1025-1038

Showing the most recent 10 out of 867 publications